Account
Inquiry
Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist currently under development for type 2 diabetes treatment. Our tirzepatide 15mg formulation offers researchers high-quality material for clinical studies and pharmacological research.
The compound demonstrates superior efficacy in glucose control and weight reduction compared to selective GLP-1 receptor agonists like dulaglutide. Tirzepatide 15mg exhibits greater affinity for GIP receptors while maintaining significant GLP-1 receptor activity, creating a synergistic effect that enhances metabolic outcomes.
Structurally similar to semaglutide, tirzepatide 15mg features a lysine side chain with PEG modification that increases water solubility. This modification contributes to the peptide's extended half-life and sustained pharmacological activity, making it suitable for once-weekly administration in clinical settings.
Clinical trials have demonstrated tirzepatide's remarkable weight loss potential. In the SURMOUNT-1 study, participants receiving the 15mg dose achieved average weight reduction of 20.9% after 72 weeks. These findings have led to FDA Fast Track designation for obesity treatment applications.
Our tirzepatide 15mg is supplied as a white lyophilized powder with 99% purity, meeting pharmaceutical grade standards. The product is strictly for research use only and not intended for human consumption. Researchers should handle all materials according to appropriate laboratory safety protocols.
The dual agonist mechanism of tirzepatide 15mg represents a significant advancement in metabolic disorder therapeutics. By simultaneously targeting both GIP and GLP-1 pathways, this compound offers researchers a powerful tool for investigating novel treatment approaches for diabetes and obesity-related conditions.
